" class="no-js "lang="en-US"> CMR Surgical - Medtech Alert
Thursday, September 25, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
CMR Surgical | Pharmtech Focus

CMR Surgical

About CMR Surgical

CMR Surgical

CMR Surgical is the UK’s leading surgical robotics company. Our ambition is to extend the benefits of laparoscopic surgery to millions more people every year.

Our next-generation robotic system, Versius, has been designed to significantly increase the volume and range of supported procedures, making the benefits of robotic minimal access surgery universally accessible and affordable.

To find out more, or to join our world-class team, visit: www.cmrsurgical.com

Related Story

Fundraising

 CMR Surgical Raises $600 Million in Series D Financing | Pharmtech Focus

CMR Surgical Raises $600 Million in Series D Financing

June 29 2021

CMR Surgical (CMR or “the Company”), a global surgical robotics business, today announces that it […]